HEAL Initiative: Translating Addiction Epidemiology, Prevention, Treatment, and Recovery Research into Practice (R61/R33 - Clinical Trial Optional)
Grant Opportunity Analysis
The National Institutes of Health, through HHS and the HEAL Initiative, is funding an R61/R33 grant to translate addiction epidemiology, prevention, treatment, and recovery research into practice to help address the opioid and stimulant crisis and overdose events. The work is intended to advance scalable, evidence-based interventions and implementation strategies at the individual, provider, organizational, community, or system level, including efforts relevant to chronic pain co-occurring with substance use. The phased award begins with an R61 feasibility and preparatory period and can transition to an R33 larger-scale phase only if required milestones are met, with a detailed Timeline and Milestone Plan expected and foreign entities excluded while foreign components are allowed. Applications are due February 10, 2029, and the contact listed is NIDA-26-063@nih.gov; the R61 phase supports up to 2 years at $350,000 per year and the R33 phase up to 5 years at $750,000 per year.
Eligible Applicants
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.